A doctor’s hand corrects a statement with a pen from “I don’t have actionable…” to “I now have actionable genomic information to better diagnose my patient’s lung disease.” In the background, a CT scan of a lung with a lesion is visible.

NEW DATA: Percepta Genomic Sequencing Classifier

AABIP 2022 Presentation

Date: August 12 2022, 6:30-7:15am CT
Presented by: Dr. Sonali Sethi, Dr. Bill Bulman

Speakers will review the Percepta Genomic Sequencing Classifier (GSC) performance in lung nodule patient management and the role of the Envisia Genomic Classifier in the diagnosis and prognosis of ILD patients.

ATS Webinar

Presented by: Fayez Kheir, MD & Mary Beth Scholand, MD.

In this webinar speakers review published data on the Envisia Genomic Classifier, updates from the recent IPF/PPF clinical guideline, and how they have integrated the classifier into their practice.
Logo for Envisia Genomic Classifier

Envisia detects genomic UIP pattern to improve ILD diagnostic and prognostic confidence.

Logo for Percepta Lung Cancer Diagnostics portfolio

Percepta GSC stratifies the risk of lung cancer to guide patient management for when bronchoscopy is inconclusive.


Percepta Nasal Swab brings genomic objectivity to lung nodule risk assessment with a simple, non-invasive tool.


Percepta Genomic Atlas guides personalized treatment earlier in lung cancer diagnosis.

Transform uncertainty into confidence

Veracyte offers a suite of actionable genomic tests that can offer greater confidence and clarity at every step of your lung cancer and interstitial lung disease patient management.